ZW25 in Women With Endometrial Cancers

Phase 2 Completed 16 enrolled Memorial Sloan Kettering Cancer Center Zymeworks BC Inc. · collab

Non-randomizedCrossoverOpen-labelTreatment

Summary

This study is being done to test the drug ZW25 and look at whether this drug is effective in women with HER2-overexpressed endometrial cancer or carcinosarcoma that has been treated in the past.

Timeline

Start: 2020-08-12
Primary completion: 2024-03-08
Completion: 2024-03-08

Outcome

Missed primary endpoint

paper This study did not meet its primary efficacy endpoint. PMID 38262242 ↗

Publications

Lumish M, Chui MH, Zhou Q, Iasonos A, Sarasohn D, Cohen S, Friedman C, Grisham R, Konner J, Kyi C, Rubinstein M, Troso-Sandoval T, Aghajanian C, Makker V. A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2). Gynecol Oncol. 2024 Mar;182:75-81. doi: 10.1016/j.ygyno.2023.12.028. Epub 2024 Jan 22.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Zanidatamab	Monoclonal antibody	20 mg/kg	Intravenous